Fenofibrate Tablet, Coated Breastfeeding

There are high number of clear evidence that breastfeeding provides best nutrition that you can give to your baby. It is also evident that lactation is good for mothers health as well. Evolution has designed breastfeeding in a way that it caters all nutritional need of your child. However modern medicine is quite new for evolution, that is why mothers body is not well prepared to filter unnecessary chemical found in medicines. It becomes a necessity to figure out which drug is safe and which drug is dangerous for your newborn while nursing. In this article we will understand function of Fenofibrate Tablet, Coated and its suitability with breastfeeding.

What is Fenofibrate Tablet, Coated used for?

Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1). For treatment of adult patients with severe hypertriglyceridemia ( 1.2). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1). 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. 1.2 Severe Hypertriglyceridemia Fenofibrate tablets are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. 1.3 Important Limitations of Use Fenofibrate at a dose equivalent to 145 mg of fenofibrate tablets was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus [see Warnings and Precautions (5.1)].

I am breastfeeding mother and I am using Fenofibrate Tablet, Coated. Can it have any bad effect on my kid? Shall I search for better alternative?

Fenofibrate Tablet, Coated low risk for breastfeeding
Fenofibrate is the one and only active ingredient present in Fenofibrate Tablet, Coated. Fenofibrate in itself is a low risk drug for lactation so it is easy to understand that Fenofibrate Tablet, Coated also comes in category of Low Risk item while breastfeeding. Below is the summary of Fenofibrate in breastfeeding.

Fenofibrate Tablet, Coated Breastfeeding Analsys

Fenofibrate while Breastfeeding

Low Risk

CAS Number: 49562-28-9

Fenofibrate, like other fibrates, decreases elevated blood lipids (triglycerides and cholesterol) by increasing the activity of lipases that catabolize triglyceride-rich lipoproteins and slightly decreasing cholesterol biosynthesis (AEMPS 2017, BGP 2015, Miller 1998). In general, fibrates have a discrete effect on the increase of high density lipoprotein (HDL) concentration and the reduction of low density lipoprotein (LDL). Since the last update we have not found published data in relation to breastfeeding. Its high binding to plasma proteins makes it unlikely it will pass into breast milk. Cholesterol levels in milk are very stable even in hypercholesterolemic women and are not severely affected by diet or nutritional status of the mother, suggesting that 3 is synthesized, at least in part, in the mammary gland (Lawrence 2016, p 289-90).It is not probable therefore, but it is not known if the fibrates are able to alter the lipid composition of the milk. Infants need to ingest large amounts of cholesterol, as it is critical to the proper development of the nervous system, cell membranes and is a precursor of several hormones and vitamins. Until there is more data in relation to breastfeeding, it is prudent to avoid using it, at least while breastfeeding exclusively. Suspending the pharmacological treatment of hyperlipidemia during breastfeeding is not likely to alter the long-term outcome of the disease, especially when breastfeeding can be considered therapeutic (Lawrence 2016, p.393). It is advisable to follow a lipid-lowering diet. In case of administering a fibrate during breastfeeding it is advisable to choose those with a shorter half-life: bezafibrate, gemfibrozil.

Fenofibrate Tablet, Coated Breastfeeding Analsys - 2

Fenofibrate while Breastfeeding

CAS Number: 49562-28-9

No relevant published information exists on the use of fenofibrate during breastfeeding. Because of a concern with disruption of infant lipid metabolism, fenofibrate is best avoided during breastfeeding. An alternate drug is preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be avoided during fenofibrate therapy and for 5 days after the final dose.

What should I do if I am breastfeeding mother and I am already exposed to Fenofibrate Tablet, Coated?

During whole lactation period you shall first discuss with your doctor and then together you shall decide whether you shall take that drug or not however if you have already taken Fenofibrate Tablet, Coated then you shall inform your doctor, But you should not be worried too much as Fenofibrate Tablet, Coated comes in category of low risk drug.

I am nursing mother and my doctor has suggested me to use Fenofibrate Tablet, Coated, is it safe?

Fenofibrate Tablet, Coated comes in category of low risk and if your doctor is aware that you are breastfeeding it should be ok to use without much concerns.

If I am using Fenofibrate Tablet, Coated, will my baby need extra monitoring?

Not much

Who can I talk to if I have questions about usage of Fenofibrate Tablet, Coated in breastfeeding?

National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week